US Patent Issued to Pieris Pharmaceuticals on Dec. 2 for "Fusion proteins specific for CD137 and GPC3" (German Inventors)

ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,486,330, issued on Dec. 2, was assigned to Pieris Pharmaceuticals GmbH (Hallbergmoos, Germany).

"Fusion proteins specific for CD137 and GPC3" was invented by Rachida Siham Bel Aiba (Munich), Birgit Bossenmaier (Seefeld, Germany), Thomas Jaquin (Erding, Germany), Janet Peper-Gabriel (Freising, Germany), Eva-Maria Hansbauer (Freising, Germany), Corinna Schlosser (Freising, Germany) and Shane Olwill (Freising, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides fusion proteins specific for both CD137 and GPC3, which fusion protein can be used to co-stimulate lymphocyte activation in a GPC3-target-dependent manner. Such fusion prot...